Japanese Journal of Clinical Oncology · 2014 · 20 citations · 10 references
MedicineOncologyPharmacotherapyCancer PharmacologyNeoplasiaThoracic OncologyDiffuse Lung DiseaseInterstitial Lung DiseaseInterstitial Lung Disease ImagingLung CancerLung Cancer PharmacotherapyMalignant NeoplasmsAlk InhibitionAlveolar SeptaAnaplastic Lymphoma Kinase InhibitionAnaplastic Lymphoma Kinase InhibitorsBronchoalveolar Lavage AnalysisNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentTransbronchial Biopsy
A 75-year-old woman with anaplastic lymphoma kinase (ALK)-rearranged Stage IV lung adenocarcinoma was administered the selective anaplastic lymphoma kinase inhibitor, alectinib, as a third-line treatment in a Phase 1-2 study. On the 102nd day, chest computed tomography showed diffuse ground glass opacities. Laboratory data revealed high serum levels of KL-6, SP-D and lactate dehydrogenase without any clinical symptoms. There was no evidence of infection. Marked lymphocytosis was seen in bronchoalveolar lavage fluid analysis, and transbronchial lung biopsy showed mild thickening of alveolar septa and lymphocyte infiltration. Interstitial lung disease was judged to be related to alectinib based on improvements in imaging findings and serum biomarkers after discontinuation of alectinib. To our knowledge, this is the first reported case of alectinib-induced interstitial lung disease. Alectinib is a promising drug for ALK-rearranged non-small cell lung cancer. Clinical trials of this selective anaplastic lymphoma kinase inhibitor will facilitate the meticulous elucidation of its long-term safety profile.
10
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature · 2007 · 5.4K citations
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text
Medicine, Oncology, Pharmacology +15
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi, Manabu Soda, Yoshihiro Yamashita et al. · New England Journal of Medicine · 2010 · 1.2K citations · Full text
Shirish M. Gadgeel, Leena Gandhi, Gregory J. Riely et al. · The Lancet Oncology · 2014 · 695 citations
Medicine, Oncology, Pharmacology +16
James G. Christensen, Helen Y. Zou, Maria E. Arango et al. · Molecular Cancer Therapeutics · 2007 · 647 citations
Medicine, Oncology, Pharmacology +17